Breaking News on Supplements, Health & Nutrition - Europe US edition | APAC edition

Trends > Health claims

EFSA rejects two new 13.5 claims on ‘transit’ and ‘vaginal moisture’

By Nathan Gray , 27-Sep-2012
Last updated on 27-Sep-2012 at 15:46 GMT2012-09-27T15:46:08Z

The European Food Safety Authority (EFSA) has rejected two health claims dossiers for food supplements that claim to ‘improve transit’ and ‘reduction of vaginal dryness’.

The European regulatory authority’s panel on Dietetic Products, Nutrition and Allergies (NDA) the applications from French firm Vivatech and Swiss-based Nutrilinks.

Vivatech had applied to EFSA claiming that its Transitech food supplement “improves transit and durably regulates it,” while Nutrilinks had asked EFSA to provide a scientific opinion on a health claim related to its Femilub supplement for the maintenance of vaginal moisture. 

However EFSA's NDA panel rejected both claims, stating that Vivatech’s ‘Transitech’ had not been sufficiently characterised in the dossier, and that Nutrilinks had provided no human intervention studies for its food supplement ‘Femilub’.

“No human intervention studies were provided from which conclusions could be drawn for the scientific substantiation of the claim,” said EFSA. “A cause and effect relationship has not been established between the consumption of “Femilub” and maintenance of vaginal moisture.”

The Transitech supplement was said to contain “dried parts of Rheum palmatum L. and/or Rheum officinale Baillon and/or their hybrids standardised for hydroxyanthracene derivatives, of Althaea officinalis L., of Rosa centifolia L., ofOcimum basilicum L., of Coriandrum sativum L., dried juice of Cynara scolymus L. standardised for cynarine, Saccharomyces cerevisiae subsp. cerevisiae UVAFERM SC,Bifidobacterium longum R0175 and Lactobacillus helveticus R0052.”

In response to the application the NDA panel said it considered the information provided by Vivatech to be “insufficient to establish that Saccharomyces cerevisiae subsp. cerevisiaeUVAFERM SC was sufficiently characterised.”

“The Panel considers that if in a combination of several microorganisms and/or ingredients one microorganism or ingredient used in the combination is not sufficiently characterised, then the combination is considered to be not sufficiently characterised,” EFSA added.

Related products

Live Supplier Webinars

Polyphenols tipped to become the way to innovate in Sports Nutrition
Alpha & Omega in Sports Nutrition – Using Omega 3’s and A-GPC to improve performance and recovery.
KD Pharma
Orally bioavailable standardized botanical derivatives in sport nutrition: special focus on recovery in post-intense physical activities
Collagen in motion: move freely and keep your injuries in check
Leading manufacturer of gelatine and collagen peptides
Life’s too short for slow proteins. Whey proteins hydrolysates: Fast delivery for enhanced performance
Arla Foods Ingredients
What it Takes to Compete and Win in Today’s Sports Nutrition Market
Sports Nutrition Snapshot: Key regional drivers and delivery format innovations
William Reed Business Media
Gutsy performance: How can microbiome modulation help athletes and weekend warriors
William Reed Business Media
Pushing the boundaries: Where’s the line between ‘cutting edge nutrition’ and doping
William Reed Business Media

On demand Supplier Webinars

High-amylose maize starch may reduce the risk of type 2 diabetes: what does this qualified health claim mean?
Balancing Innovation and Risk in Sports Nutrition Ingredients
Explaining bio-hacking: is there a marketing opportunity for food companies?
William Reed Business Media
Personalized Nutrition – how an industry can take part in shaping the future of Nutrition
BASF Nutrition & Health
Find out Nutritional and ingredient lifecycle solutions and strategies!
Is the time rIpe for I-nutrition?
William Reed Business Media
The Advantage of Outsourcing Fermentation-based Manufacturing Processes
Evonik Health Care
All supplier webinars